The Effect of COVID-19 Severity, Associated Serum Autoantibodies and Time Interval after the Disease on the Outcomes of Fresh Oocyte ART Cycles in Non-Vaccinated Patients.

Publication date: Jun 29, 2023

It is assumed that SARS-CoV-2- and COVID-19-associated autoimmune processes may affect the outcomes of assisted reproductive technology (ART) cycles. This observational prospective study included 240 infertile patients: 105 patients had no history of COVID-19 (group 1) and 135 patients had experienced COVID-19 (group 2) in a mild (n = 85) or moderate (n = 50) form less than 12 months prior to oocyte retrieval. Using ELISAs, the profiles of their serum autoantibodies were determined, including antiphospholipid antibodies and antibodies to nuclear and thyroid antigens. The parameters of oogenesis and embryogenesis, as well as the pregnancy and childbirth rates, did not differ between groups 1 and 2, and also between the subgroups with different severities of COVID-19. However, when oocyte retrieval was performed less than 180 days after COVID-19, a higher proportion of poor-quality blastocysts was obtained (p = 0. 006). A high risk of early miscarriage was found in the patients with moderate COVID-19. In group 2, IgG antibodies to annexin V, phosphatidylethanolamine (PE), and TSHr were detected more often than in group 1 (p = 0. 035; p = 0. 028; and p = 0. 033, respectively), and a weak inverse correlation was revealed between anti-PE IgG and the number of oocytes and zygotes obtained. The results of the study suggest a possible adverse effect of COVID-19 and its associated autoantibodies on the outcomes of fresh oocyte ART cycles and early pregnancy, which depends on the severity of COVID-19 and the time interval after the disease.

Open Access PDF

Concepts Keywords
Embryogenesis assisted reproductive technology
Miscarriage autoantibodies
Nuclear COVID-19
Vaccinated infertility
reproductive outcomes


Type Source Name
disease MESH COVID-19
disease VO time
disease VO vaccinated
disease IDO history
disease IDO quality
disease MESH miscarriage
drug DRUGBANK Phosphatidylethanolamine
disease MESH infertility
disease MESH Severe Acute Respiratory Syndrome
disease VO organization
disease MESH inflammation
pathway KEGG Apoptosis
disease MESH cytokine storm
drug DRUGBANK Coenzyme M
disease VO Betacoronavirus
drug DRUGBANK Angiotensin II
drug DRUGBANK Serine
drug DRUGBANK Rasagiline
disease MESH premature ovarian failure
disease VO pregnant women
disease MESH pregnancy complications
disease MESH infection
disease MESH oxidative stress
disease VO Viruses
disease IDO production
disease VO organ
disease MESH autoimmune diseases
disease MESH hyperthyroidism
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH antiphospholipid syndrome
drug DRUGBANK Adenosine 5′-phosphosulfate
disease VO Hormone
drug DRUGBANK Follitropin
disease MESH contraindications
disease MESH morbid obesity
disease MESH HIV infection
disease MESH coronavirus infection
disease IDO assay
disease MESH sore throat
disease MESH viral infection
disease MESH re infection
disease MESH Twin pregnancy
disease VO frequency

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *